Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis-Reference-Cited by-同舟云学术

Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis

Published:2021-06-17 Issue:7 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Abdelwahab Mahmoud Tareq¹^ORCID,Court Richard¹,Everitt Daniel²,Diacon Andreas H.³⁴,Dawson Rodney⁵,Svensson Elin M.⁶⁷,Maartens Gary¹⁸^ORCID,Denti Paolo¹^ORCID

Affiliation:

1. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa

2. Global Alliance for TB Drug Development, New York, New York, USA

3. Department of Medicine, Stellenbosch University, Tygerberg, South Africa

4. Task Applied Science, Bellville, South Africa

5. Division of Pulmonology and Department of Medicine, University of Cape Town Lung Institute, Mowbray, Cape Town, South Africa

6. Department of Pharmacy, Radboud Institute of Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands

7. Department of Pharmacy, Uppsala University, Uppsala, Sweden

8. Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Abstract

Clofazimine is classified as a WHO group B drug for the treatment of rifampin-resistant tuberculosis. QT prolongation, which is associated with fatal cardiac arrhythmias, is caused by several antitubercular drugs, including clofazimine, but there are no data quantifying the effect of clofazimine concentration on QT prolongation.

Funder

Bill and Melinda Gates Foundation

National Research Foundation

Newcastle University | Wellcome Trust Centre for Mitochondrial Research

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02687-20

Reference23 articles.

1. World Health Organization. 2020. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. World Health Organization, Geneva, Switzerland.

2. Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline

3. Clofazimine pharmacokinetics in patients with TB: dosing implications

4. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis

5. Clofazimine induced cardiotoxicity-a case report;Choudhri S;Lepr Rev,1995

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis;Antimicrobial Agents and Chemotherapy;2024-01-10

2. Pharmacokinetics and Safety of Group A and B Anti-Tuberculosis Drugs Used in Treatment of Rifampicin-Resistant Tuberculosis during Pregnancy and Post-Partum: A Narrative Review;Pathogens;2023-11-24

3. QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies;Antimicrobial Agents and Chemotherapy;2023-07-18

4. Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis;Antimicrobial Agents and Chemotherapy;2023-07-18

5. Updated considerations in the diagnosis and management of tuberculosis infection and disease: integrating the latest evidence-based strategies;Expert Review of Anti-infective Therapy;2023-05-08